Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma

NCT03952572 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT03952572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03952572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Multi-center Randomized Non-inferiority Study to Compare Efficacy and Safety of Pegylated Liposomal Doxorubicin Versus Doxorubicin for Newly Diagnosed Peripheral T-cell Lymphoma
Lead sponsor
Peking University
Phase
Phase 3
Overall status
Unknown status
Start date
May 10, 2019
Completion date
April 30, 2023
Enrollment
244 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma